Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress



    
    Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant

    
    SAN DIEGO, Oct. 8 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX:
NVN) today presented positive data from preclinical studies using its
proprietary Toll-like Receptor 3 agonist, Poly IC-Poly Arginine (Poly-ICR), at
the World Vaccine Congress 2008 in Lyon, France.  Study results demonstrated
Poly-ICR to be a potent vaccine adjuvant targeting the Toll-like Receptor 3
(TLR3) pathway.  Data showed that Poly-ICR, in combination with model
antigens, elicits strong anti-target antibody and CD8 T-cell immune responses.
 These findings demonstrate the versatility of Poly-ICR, suggesting that the
compound may possess broad potential for use in both therapeutic and
prophylactic vaccines.
    
    (Logo:  http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)
    
    Additional study findings presented today by Peter Emtage, Ph.D.,
Nventa's vice president of research and development, include:

    
    -- Poly-ICR is stable and resistant to degradation by RNAses in
       human serum;
    -- Poly-ICR induces significant cytokine and chemokine production;
    -- Poly-ICR matures dendritic cells, known as "the teachers of the
       immune system".
    
    In addition to incorporating Poly-ICR into future internal product
candidates, Nventa is pursuing the development of Poly-ICR for topical
application for the treatment of genital warts (GW) and actinic keratosis, a
premalignant condition of the skin.
    The company is also currently providing access to Poly-ICR to multiple
leading vaccine developers in the U.S. and abroad, who are evaluating Poly-ICR
for potential use into a wide range of vaccine products.
    "These findings have confirmed the potency of Poly-ICR and highlighted
the broad applicability of this compound for potential use in therapeutic and
prophylactic vaccines," said Gregory M. McKee, president and chief executive
officer at Nventa.  "While we are advancing Poly-ICR for our internal
development and use, we've been extremely pleased with the interest in
Poly-ICR that has been shown by outside parties.  We are currently working
with vaccine developers worldwide to enable their studies with Poly-ICR and we
believe this product will evolve into a revenue generating opportunity for
Nventa in the near future."
    
    About Poly-ICR:
    
    Poly-ICR is a Toll-like Receptor 3 (TLR3) agonist that when combined with
a disease-specific antigen can induce both cytotoxic T-cell and antibody
(B-cell) immune responses against that antigen.  Cytotoxic T-cells, also
referred to as CD8 T-cells, are required to target and eliminate pathogen-
infected or cancerous cells.  Antibodies, or B-cells, are required to protect
against an infection caused by a pathogen.  Poly-ICR, therefore, has potential
utility in both the therapeutic and prophylactic areas of immunotherapy and
vaccine development.  This novel and potent immunomodulator works with the
immune system to induce dendritic cell maturation, along with a broad range of
inflammatory cytokines and chemokines, to facilitate the prevention and
treatment of infectious diseases or cancer.
    Data generated using Poly-ICR, in combination with a tumor-associated
antigen, have demonstrated that the addition of the adjuvant potently
increases the antigen-specific CD8 T-cell levels, which correlated with
regression of tumors and prevention of tumor growth in mouse models.  Poly-ICR
is differentiated from other Poly IC compositions by its high stability and
potency in human sera, as well as its consistency in physical-chemical
properties.  Nventa has successfully manufactured research and development
lots of Poly-ICR and expects that its current manufacturing process can be
used to produce future cGMP material.
    
    About Nventa Corporation:
    
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV).  The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN.  For more information about Nventa, please
visit http://www.nventacorp.com.
    This press release contains statements which may constitute forward-
looking information under applicable Canadian securities legislation or
forward-looking statements within the meaning of the United States Private
Securities Litigation Reform Act of 1995.  Such forward-looking statements or
information may include financial and other projections as well as statements
regarding the company's future plans, objectives, performance, revenues,
growth, profits, operating expenses or the company's underlying assumptions.
The words "may", "would", "could", "will", "likely", "expect," "anticipate,"
"intend", "plan", "forecast", "project", "estimate" and "believe" or other
similar words and phrases may identify forward-looking statements or
information.  Persons reading this press release are cautioned that such
statements or information are only predictions, and that the company's actual
future results or performance may be materially different.
    Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning: Poly-ICR's
potential for use in both therapeutic and prophylactic vaccines; our plans to
incorporate Poly-ICR into future internal product candidates; the development
of Poly-ICR for topical application for the treatment of GW and actinic
keratosis; our belief that Poly-ICR will evolve into a revenue generating
opportunity for Nventa in the near future; Poly-ICR's ability to induce both
cytotoxic and antibody immune responses; and our expectation that our
manufacturing process can be used to produce cGMP Poly-ICR.
    Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
events or developments to be materially different from results, events or
developments expressed or implied by such forward-looking statements or
information.  Such factors include, among others, that we may not be able to
raise required capital; that we may not procure partners that use Poly-ICR in
their vaccines and, if we do, that Poly-ICR will not be useful in such
vaccines; that approvals by government agencies such as the FDA that are
needed before products can be tested in clinical trials may not be obtained in
a timely manner or at all or will be conditioned in a manner that would impair
our ability to advance Poly-ICR; that Poly-ICR may not be found safe and
effective after extensive clinical trials; that we may not be able to
incorporate Poly-ICR into future internal product candidates; that it will not
be possible to develop Poly-ICR for topical application for the treatment of
GW or actinic keratosis; that Poly-ICR will not evolve into a revenue
generating opportunity for Nventa in the near future or ever; our dependence
on third parties to manufacture Poly-ICR; that our manufacturing processes may
not be validated for use in producing cGMP materials; that we may not retain
key personnel; and other factors as described in detail in our filings with
the Canadian securities regulatory authorities at http://www.sedar.com.
    Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that we will be able to raise required capital; that we will procure
partners that use Poly-ICR in their vaccines and that Poly-ICR will be useful
in such vaccines; that approvals by government agencies such as the FDA that
are needed before products can be tested in clinical trials will be obtained
in a timely manner and in a manner that will not impair our ability to advance
Poly-ICR; that Poly-ICR will be found safe and effective; that we will be able
to incorporate Poly-ICR into future internal product candidates; that it will
be possible to develop Poly-ICR for topical application for the treatment of
GW and actinic keratosis; that Poly-ICR will evolve into a revenue generating
opportunity for Nventa in the near future; that we will be able to engage
third party manufacturers who will successfully manufacture Poly-ICR on
reasonable terms and in a timely manner; that our manufacturing processes will
be validated for use in producing cGMP materials; and that we will retain key
personnel.
    In the event that any of these assumptions prove to be incorrect, or in
the event that we are impacted by any of the risks identified above, we may
not be able to continue in our business as planned.
    For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, including our 2007 Annual
Information Form filed on SEDAR at http://www.sedar.com.
    All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
by law.




For further information:

For further information: Donna Slade, Director, Investor Relations of
Nventa Biopharmaceuticals Corporation, +1-858-202-4945, dslade@nventacorp.com;
or Media, Tim Brons of Vida Communication, +1-415-675-7400,
tbrons@vidacommunication.com; or Michael Moore of The Equicom Group,
+1-416-815-0700, Ext. 241, mmoore@equicomgroup.com, both for Nventa
Biopharmaceuticals Corporation Web Site: http://www.nventacorp.com

Organization Profile

NVENTA BIOPHARMACEUTICALS CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890